IGF1 and acromegaly: In a large, randomized, double-blind, Phase III trial (core phase of this study), pasireotide long-acting release (LAR) was significantly superior to octreotide LAR at providing GH <2.5 μg/L and normal IGF-1 at month 12 in medically naïve patients with acromegaly [14].